Need to keep on prime of the science and politics driving biotech right this moment? Enroll to get our biotech e-newsletter in your inbox.
Hello! It’s Meghana. At this time, some superb intel on Merck’s Ebola vaccine: Seems, it could scale back threat of loss of life, even after an individual has been contaminated. Additionally, buyers wager on one other weight problems drug — this time from BioAge, which is combining Zepbound with a capsule that retains muscle losing at bay.
The necessity-to-know this morning
- Biogen reported earnings for the fourth quarter and 2023.
- Regulators in Europe approved Casgevy, a CRISPR-based gene-editing therapy, for individuals with sickle cell illness and beta thalassemia. Casgevy is made by Vertex Prescription drugs and CRISPR Therapeutics.
- The FDA extended a review of Rocket Prescription drugs’ gene remedy, known as Kresladi, by three months to June 30, to permit extra time for the evaluate of producing data. Kresladi is being developed to deal with leukocyte adhesion deficiency-I, a uncommon, genetic illness that causes immune deficiency in youngsters.
- Roivant and Incyte additionally reported earnings.
- AI drug discovery agency Exscientia fired CEO Andrew Hopkins for trigger following an investigation that discovered he had “inappropriate” relationships with two firm staff. David Nicholson, chairman of Exscientia’s board, additionally resigned as a result of he had prior information of Hopkins’ relationships however didn’t notify the corporate.
BioAge’s $170 million Sequence D for GLP-1 combo capsule
BioAge, a California biotech growing a mixture remedy with the blockbuster weight problems drug Zepbound, simply raised a $170 million Sequence D spherical. Its lead candidate, azelaprag, is supposed to assist optimize weight reduction from GLP-1 medication in order that muscle mass is preserved. BioAge is growing medication for neuroinflammation as properly.
This funding spherical consists of Sofinnova Investments, Eli Lilly and Amgen’s enterprise arms, and former investor Andreessen Horowitz. Though BioAge has a number of applications, it was the azelaprag-Zepbound mixture that sparked investor curiosity.
Azelaprag mimics the hormone apelin, which is secreted in response to train. It performs a job in regulating metabolism and muscle biology. Apelin ranges dwindle with age — so BioAge, whose medication intention to maintain the consequences of ageing at bay — is .
Learn extra.
KalVista’s swelling drug performs properly in section 3
KalVista Prescription drugs’ therapy for the acute swelling episodes seen in hereditary angioedema carried out properly in Section 3 research — that means that the corporate will submit a advertising software for the drug, known as sebetralstat, by the center of the yr. Signs started to abate between 1.6 and 1.8 hours after sufferers took the oral capsule, in comparison with 6.7 hours with placebo. There have been no critical unintended effects from the drugs.
Proper now, the most typical strategy to deal with a swelling episode from hereditary angioedema is a generic drugs known as icatibant, which is injected subcutaneously. It takes about two hours for symptom aid to start.
Though the market is small, gross sales for sebetralstat might hit $600 million within the U.S. and Europe, Leerink analysts say. Notably, Intellia Therapeutics is growing a CRISPR-based therapy for hereditary angioedema that has the potential to be healing.
Learn extra.
Ebola vaccine works even in individuals who had already been contaminated
A brand new research exhibits that folks vaccinated towards Ebola with a single dose of Merck’s Ervebo are far much less prone to die than those that aren’t vaccinated, even when they do develop the illness.
The analysis, printed in Lancet Infectious Ailments, is predicated on knowledge from the 2018-2020 Ebola Zaire outbreak within the Democratic Republic of the Congo. It confirmed that the inoculation halved the chance of dying amongst individuals who had acquired the vaccine earlier than growing signs — together with those that solely acquired the vaccine only a day or two earlier than getting sick. About 27% of people that had been vaccinated inside two days of changing into symptomatic died, in comparison with 56% in those that have been unvaccinated.
“That’s an enormous discovering,” the research’s first writer advised STAT. “We all know now that vaccination is healthier late than by no means. So that is another reason to make use of the Ebola vaccine.”
Learn extra.
Gilead buying CymaBay for $4.3 billion
Gilead Sciences will purchase CymaBay Therapeutics for $4.3 billion, based mostly totally on the latter’s lead candidate, seladelpar, which goals to deal with a uncommon autoimmune liver illness known as main biliary cholangitis. The FDA is reviewing a advertising software for seladelpar, with an approval anticipated by Aug. 14.
This acquisition boosts Gilead’s liver illness portfolio, which incorporates its therapies for hepatitis C. It additionally represents a redemption for CymaBay, which skilled some critical setbacks in 2019 when seladelpar didn’t deal with MASH, previously generally known as NASH. In 2022, CymaBay’s inventory was about $2 a share. The take care of Gilead locations shares for CymaBay at $32.50 — 27% larger than they have been simply final week.
Learn extra.
Extra reads
- Proteins might predict who will get dementia 10 years later, research finds, Reuters
- In wake of Reata buyout, Biogen’s key launch Skyclarys passes muster in EU, FierceBiotech
- CSL’s ‘most bold’ section 3 trial ends in failure for coronary heart assault drug, FierceBiotech
